- Home
- IQ vs HRMY Comparison
IQ vs HRMY Comparison
Compare IQ & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IQ | HRMY |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IQ | HRMY |
|---|---|---|
| Price | $1.93 | $36.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $2.91 | ★ $49.75 |
| AVG Volume (30 Days) | ★ 9.3M | 618.6K |
| Earning Date | 02-26-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.44 |
| EPS | N/A | ★ 3.17 |
| Revenue | ★ $3,808,085,043.00 | $825,944,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | $2.47 | $16.28 |
| P/E Ratio | ★ N/A | $11.78 |
| Revenue Growth | N/A | ★ 21.13 |
| 52 Week Low | $1.50 | $25.52 |
| 52 Week High | $2.84 | $40.87 |
Technical Indicators
Market Signals| Indicator | IQ | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 42.22 | 44.70 |
| Support Level | $1.88 | $36.32 |
| Resistance Level | $2.19 | $38.37 |
| Average True Range (ATR) | 0.08 | 1.23 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 14.57 | 35.50 |
Price Performance
Historical ComparisonAbout IQ iQIYI Inc.
Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.